{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T04:04:50Z","timestamp":1783224290402,"version":"3.54.6"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","funder":[{"DOI":"10.13039\/501100000646","name":"Japan Society for the Promotion of Science London","doi-asserted-by":"crossref","award":["00000000"],"award-info":[{"award-number":["00000000"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Cabozantinib is highly effective against advanced renal cell carcinoma (RCC). However, approximately 60% of the patients require a dose reduction due to severe adverse events. Although associations between trough concentrations of cabozantinib and its efficacy and safety have been reported in other countries, reports on Japanese patients are unavailable. Therefore, we investigated the association of cabozantinib trough concentration with therapeutic efficacy and adverse events in Japanese patients with RCC and evaluated the usefulness of therapeutic drug monitoring.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>In this prospective observational study, we measured the trough concentrations of cabozantinib in 10 Japanese patients with RCC enrolled between May 2022 and September 2023. The associations of trough concentration with treatment response, as determined by RECIST 1.1, and the occurrence of grade 2 or higher adverse events were assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Trough concentration was higher in patients with controlled cancer than in those with progressive cancer (1024 \u00b1 352 versus 457 \u00b1 216 ng\/mL, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.035). In addition, patients with grade 2 or higher adverse events showed a significantly higher trough concentration than those without (1560 \u00b1 513 versus 807 \u00b1 319 ng\/mL, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.032). In particular, grade 2 or higher dysgeusia, anorexia, fatigue, and dyspepsia significantly correlated with trough concentrations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This is the first clinical study to demonstrate a correlation between cabozantinib trough concentration, therapeutic efficacy, and adverse events in Japanese patients with RCC. The therapeutic drug monitoring of cabozantinib could be useful for improving therapeutic efficacy and avoiding serious adverse events.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001254","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:04:11Z","timestamp":1724976251000},"page":"400-406","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Association of Plasma Cabozantinib Concentration With Treatment Response and Adverse Events in Japanese Patients With Advanced Renal Cell Carcinoma"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1386-8112","authenticated-orcid":false,"given":"Shinichi","family":"Maruyama","sequence":"first","affiliation":[{"name":"Department of Bioanalytical Chemistry, Showa University Graduate School of Pharmacy, Tokyo, Japan;"},{"name":"Pharmacy and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1038-8793","authenticated-orcid":false,"given":"Hiroaki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Urology, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Japan; and"},{"name":"Department of Urology, National Defense Medical College Hospital, Saitama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuru","family":"Hiraga","sequence":"additional","affiliation":[{"name":"Pharmacy and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadatsugu","family":"Anno","sequence":"additional","affiliation":[{"name":"Urology, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tansei","family":"Sanjo","sequence":"additional","affiliation":[{"name":"Urology, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Arai","sequence":"additional","affiliation":[{"name":"Urology, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Ishida","sequence":"additional","affiliation":[{"name":"Urology, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kanno","sequence":"additional","affiliation":[{"name":"Pharmacy and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6627-1773","authenticated-orcid":false,"given":"Masaru","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Bioanalytical Chemistry, Showa University Graduate School of Pharmacy, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"key":"R1-20250509","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther."},{"key":"R2-20250509","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med."},{"key":"R3-20250509","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/s41416-018-0061-6","article-title":"Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma","volume":"118","author":"Motzer","year":"2018","journal-title":"Br J Cancer."},{"key":"R4-20250509","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol."},{"key":"R5-20250509","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/iju.14329","article-title":"Cabozantinib in advanced renal cell carcinoma: a phase II, open-label, single-arm study of Japanese patients","volume":"27","author":"Tomita","year":"2020","journal-title":"Int J Urol."},{"key":"R6-20250509","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1038\/bjc.2014.194","article-title":"Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours","volume":"110","author":"Lankheet","year":"2014","journal-title":"Br J Cancer."},{"key":"R7-20250509","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol."},{"key":"R8-20250509","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00280-018-3579-7","article-title":"Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma","volume":"81","author":"Lacy","year":"2018","journal-title":"Cancer Chemother Pharmacol."},{"key":"R9-20250509","doi-asserted-by":"crossref","first-page":"100312","DOI":"10.1016\/j.esmoop.2021.100312","article-title":"Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics\/pharmacodynamics study","volume":"6","author":"Cerbone","year":"2021","journal-title":"ESMO Open."},{"key":"R10-20250509","doi-asserted-by":"crossref","first-page":"121968","DOI":"10.1016\/j.jchromb.2020.121968","article-title":"A simple and rapid liquid chromatography-mass spectrometry method to assay cabozantinib in plasma: application to therapeutic drug monitoring in patients with renal cell carcinoma","volume":"1138","author":"Ferrer","year":"2020","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R11-20250509","doi-asserted-by":"crossref","first-page":"e5599","DOI":"10.1002\/bmc.5599","article-title":"Quantitative determination of plasma cabozantinib concentration using HPLC-UV and its application to patients with renal cell carcinoma","volume":"37","author":"Maruyama","year":"2023","journal-title":"Biomed Chromatogr."},{"key":"R13-20250509","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer."},{"key":"R14-20250509","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12032-018-1113-8","article-title":"Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma","volume":"35","author":"Igarashi","year":"2018","journal-title":"Med Oncol."},{"key":"R15-20250509","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/bjc.2014.503","article-title":"Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma","volume":"111","author":"Suttle","year":"2014","journal-title":"Br J Cancer."},{"key":"R17-20250509","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/j.cllc.2018.12.018","article-title":"Phase 1 study of cabozantinib in Japanese patients with expansion cohorts in non-small-cell lung cancer","volume":"20","author":"Nokihara","year":"2019","journal-title":"Clin Lung Cancer."},{"key":"R18-20250509","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10928-019-09659-y","article-title":"Cabozantinib exposure-response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma","volume":"46","author":"Nguyen","year":"2019","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"R19-20250509","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1634\/theoncologist.2017-0335","article-title":"Management of adverse events associated with cabozantinib therapy in renal cell carcinoma","volume":"23","author":"Schmidinger","year":"2018","journal-title":"Oncologist."},{"key":"R20-20250509","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3390\/ph15121460","article-title":"Impact of cabozantinib exposure on proteinuria and muscle toxicity in patients with unresectable hepatocellular carcinoma","volume":"15","author":"Okubo","year":"2022","journal-title":"Pharmaceuticals (Basel)."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001254","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T12:00:28Z","timestamp":1746792028000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001254","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]},"assertion":[{"value":"2024-04-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}